Edward M Lichten
The finding that the reduction within the Estrogen Receptor ER-beta/ ER-alpha ratio may be a pathologic biomarker for flairs in Crohn???s Disease has been scientifically linked, retrospectively, to 1) reduced bioavailable testosterone, 2) hypothalamic-pituitarygonadal axis dysregulation and 3) environmental toxins as probable causation. Estrogen turns
off the ER-beta and must be avoided. Bioavailable testosterone is recognized because the biomarker, the Free Androgen Index (FAI). Decreased bioavailability is calculated because the ratio of decreasing Total Testosterone levels and increasing sex-hormone-binding globulin (SHBG). The FDA medication that increases serum total testosterone without increasing estrogen is nandrolone. The FDA medication that decreases SHBG is stanozolol. Using weekly intramuscular injections, the FAI is used because the drug-related biomarker. Increases in FAI parallel the recovery and potential remission seen with 5 of seven Crohn???s patients followed for up to five years. Each had exhausted all medication and surgical options; 2 had all the complications related to their Short Bowel Syndrome. The FAI is the scientific serum drugrelated biomarker that increases with treatment directed improvement in disease. These two available anabolic steroids offer a paradigm shift beyond biologics and surgical resection; these patients may now realize the compassionate relief from the devastation of inflammatory bowel disease
Share this article
Hepatology and Pancreatic Science received 34 citations as per Google Scholar report
